| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| K Tayarani-Binazir, M J Jackson, S Rose, A C McCreary, P Jenne. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Experimental neurology. vol 226. issue 2. 2010-11-12. PMID:20843474. |
however, once dyskinesia has developed, dopamine agonists administered with l-dopa exacerbate involuntary movements. |
2010-11-12 |
2023-08-12 |
Not clear |
| K Tayarani-Binazir, M J Jackson, S Rose, A C McCreary, P Jenne. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. Experimental neurology. vol 226. issue 2. 2010-11-12. PMID:20843474. |
the dopamine partial d2/d3 agonist pardoprunox reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (mptp)-treated primates without hyperactivity, indicating that pardoprunox may alleviate dyskinesia without compromising l-dopa's beneficial actions. |
2010-11-12 |
2023-08-12 |
Not clear |
| Andrzej Bogucki, Jarosław Sławe. [Continuous dopaminergic stimulation - clinical experience]. Neurologia i neurochirurgia polska. vol 44. issue 4. 2010-11-09. PMID:20827612. |
dopamine agonists have a longer half-life than levodopa and the development of dyskinesia is delayed when they are used as monotherapy in early pd. |
2010-11-09 |
2023-08-12 |
Not clear |
| Emanuela Santini, Veronique Sgambato-Faure, Qin Li, Marc Savasta, Sandra Dovero, Gilberto Fisone, Erwan Bezar. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PloS one. vol 5. issue 8. 2010-11-04. PMID:20808799. |
in rodents, the development of dyskinesia produced by l-dopa in the dopamine-depleted striatum occurs in response to increased dopamine d1 receptor-mediated activation of the camp - protein kinase a and of the ras-extracellular signal-regulated kinase (erk) signalling pathways. |
2010-11-04 |
2023-08-12 |
Not clear |
| C A Jones, L C Johnston, M J Jackson, L A Smith, G van Scharrenburg, S Rose, P G Jenner, A C McCrear. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 20. issue 8. 2010-10-12. PMID:20434890. |
partial d(2/3) dopamine (da) receptor agonists provide a novel approach to the treatment of the motor symptoms of parkinson's disease (pd) that may avoid common dopaminergic side-effects, including dyskinesia and psychosis. |
2010-10-12 |
2023-08-12 |
rat |
| Can-Xing Yuan, Qing Ye, Jie Wang, Yan Zhang, Chong-Gang Yua. [Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. vol 6. issue 10. 2010-10-05. PMID:18847536. |
[effects of traditional chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine d2 receptor in corpora striatum of rats with levodopa-induced dyskinesias]. |
2010-10-05 |
2023-08-12 |
rat |
| Can-Xing Yuan, Qing Ye, Jie Wang, Yan Zhang, Chong-Gang Yua. [Effects of traditional Chinese herbal medicine on the neurobehavioral manifestations and the activity of dopamine D2 receptor in corpora striatum of rats with levodopa-induced dyskinesias]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. vol 6. issue 10. 2010-10-05. PMID:18847536. |
to explore the effect of traditional chinese herbal medicine (tcm) for nourishing liver and kidney, clearing meridians and removing toxic substances, on the neurobehavioral manifestations and the activity of the dopamine d2 receptor in rat with levodopa-induced dyskinesias (lid). |
2010-10-05 |
2023-08-12 |
rat |
| M Angela Cenci, K Elisabet Ohli. Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism & related disorders. vol 15 Suppl 4. 2010-09-30. PMID:20123549. |
pharmacological dopamine (da) replacement with l-dopa causes motor fluctuations and abnormal involuntary movements (dyskinesia) in the vast majority of the patients. |
2010-09-30 |
2023-08-12 |
mouse |
| Amandine Berthet, Erwan Bezar. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism & related disorders. vol 15 Suppl 4. 2010-09-30. PMID:20123563. |
dopamine receptors and l-dopa-induced dyskinesia. |
2010-09-30 |
2023-08-12 |
Not clear |
| Amandine Berthet, Erwan Bezar. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism & related disorders. vol 15 Suppl 4. 2010-09-30. PMID:20123563. |
in the majority of parkinson's disease patients, chronic dopamine replacement therapy leads to involuntary aimless movements known as l-dopa-induced dyskinesia. |
2010-09-30 |
2023-08-12 |
Not clear |
| Amandine Berthet, Erwan Bezar. Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism & related disorders. vol 15 Suppl 4. 2010-09-30. PMID:20123563. |
while mechanisms involved in dyskinesia occurrence are still unclear, dopamine receptors undoubtedly have a central role in their pathophysiology. |
2010-09-30 |
2023-08-12 |
Not clear |
| Svenja E Sander, Roger Raymond, José N Nobrega, Angelika Richte. Autoradiographic and pharmacological studies on the role of dopamine D3 receptors in genetically dystonic (dt(sz)) hamsters. Pharmacology, biochemistry, and behavior. vol 96. issue 2. 2010-09-30. PMID:20451545. |
previous examinations demonstrated periodic increases in striatal extracellular dopamine levels during dystonic attacks and changes in dopamine d1 and d2 receptor binding in the dt(sz) mutant hamster, an animal model of paroxysmal non-kinesiogenic dyskinesia in which dystonic episodes can be induced by stress. |
2010-09-30 |
2023-08-12 |
Not clear |
| Emma L Lane, Stephen B Dunnet. Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behavioural brain research. vol 213. issue 1. 2010-09-13. PMID:20434491. |
this study uses the rodent model of dyskinesia to determine whether prior dopamine agonist treatment causes long-term changes that influence the development of l-dopa mediated behaviours. |
2010-09-13 |
2023-08-12 |
rat |
| Emma L Lane, Stephen B Dunnet. Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat. Behavioural brain research. vol 213. issue 1. 2010-09-13. PMID:20434491. |
all dopamine agonists induced a contralateral rotational response on day 1, which increased in response to repeated administration but did not by themselves induce overt dyskinesias. |
2010-09-13 |
2023-08-12 |
rat |
| Ayse Ulusoy, Gurdal Sahin, Deniz Kiri. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proceedings of the National Academy of Sciences of the United States of America. vol 107. issue 29. 2010-09-01. PMID:20615977. |
under these conditions, the animals remained nondyskinetic after chronic l-dopa treatment, whereas partial intrastriatal 6-hydoxydopamine lesioned rats with comparable reduction in extracellular dopamine levels developed dyskinesias. |
2010-09-01 |
2023-08-12 |
rat |
| Béchir Jarraya, Sabrina Boulet, G Scott Ralph, Caroline Jan, Gilles Bonvento, Mimoun Azzouz, James E Miskin, Masahiro Shin, Thierry Delzescaux, Xavier Drouot, Anne-Sophie Hérard, Denise M Day, Emmanuel Brouillet, Susan M Kingsman, Philippe Hantraye, Kyriacos A Mitrophanous, Nicholas D Mazarakis, Stéphane Palf. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Science translational medicine. vol 1. issue 2. 2010-07-12. PMID:20368163. |
dopamine gene therapy for parkinson's disease in a nonhuman primate without associated dyskinesia. |
2010-07-12 |
2023-08-12 |
monkey |
| Béchir Jarraya, Sabrina Boulet, G Scott Ralph, Caroline Jan, Gilles Bonvento, Mimoun Azzouz, James E Miskin, Masahiro Shin, Thierry Delzescaux, Xavier Drouot, Anne-Sophie Hérard, Denise M Day, Emmanuel Brouillet, Susan M Kingsman, Philippe Hantraye, Kyriacos A Mitrophanous, Nicholas D Mazarakis, Stéphane Palf. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Science translational medicine. vol 1. issue 2. 2010-07-12. PMID:20368163. |
the resulting intermittent dopamine alleviates parkinsonian symptoms but is also thought to cause abnormal involuntary movements, called dyskinesias. |
2010-07-12 |
2023-08-12 |
monkey |
| Béchir Jarraya, Sabrina Boulet, G Scott Ralph, Caroline Jan, Gilles Bonvento, Mimoun Azzouz, James E Miskin, Masahiro Shin, Thierry Delzescaux, Xavier Drouot, Anne-Sophie Hérard, Denise M Day, Emmanuel Brouillet, Susan M Kingsman, Philippe Hantraye, Kyriacos A Mitrophanous, Nicholas D Mazarakis, Stéphane Palf. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Science translational medicine. vol 1. issue 2. 2010-07-12. PMID:20368163. |
in this model, we demonstrated that injection of a tricistronic lentiviral vector encoding the critical genes for dopamine synthesis (tyrosine hydroxylase, aromatic l-amino acid decarboxylase, and guanosine 5'-triphosphate cyclohydrolase 1) into the striatum safely restored extracellular concentrations of dopamine and corrected the motor deficits for 12 months without associated dyskinesias. |
2010-07-12 |
2023-08-12 |
monkey |
| Béchir Jarraya, Sabrina Boulet, G Scott Ralph, Caroline Jan, Gilles Bonvento, Mimoun Azzouz, James E Miskin, Masahiro Shin, Thierry Delzescaux, Xavier Drouot, Anne-Sophie Hérard, Denise M Day, Emmanuel Brouillet, Susan M Kingsman, Philippe Hantraye, Kyriacos A Mitrophanous, Nicholas D Mazarakis, Stéphane Palf. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Science translational medicine. vol 1. issue 2. 2010-07-12. PMID:20368163. |
gene therapy-mediated dopamine replacement may be able to correct parkinsonism in patients without the complications of dyskinesias. |
2010-07-12 |
2023-08-12 |
monkey |
| Félix Javier Jiménez-Jiménez, María de Toledo-Hera. Possible role of nondopaminergic drugs on levodopa-induced dyskinesias in Parkinson's disease. Expert review of neurotherapeutics. vol 2. issue 3. 2010-06-25. PMID:19810874. |
the main strategies for the prevention and therapy of levodopa-induced dyskinesias are related to modifications of levodopa administration or the early use of dopamine agonists. |
2010-06-25 |
2023-08-12 |
Not clear |